Phathom Pharmaceuticals (PHAT) EBITDA Margin (2023 - 2026)
Phathom Pharmaceuticals' (PHAT) quarterly EBITDA Margin came in at 26.55% in Q1 2026, up 24998.0% year-on-year from N/an in Q1 2025, and down 157.87% on a QoQ basis from 10.29% in Q4 2025.
Phathom Pharmaceuticals (PHAT) EBITDA Margin (2023 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has 4 years of EBITDA Margin data on file, last reported at 26.55% in Q1 2026.
- On a quarterly basis, EBITDA Margin rose 24998.0% year-over-year to 26.55% in Q1 2026; TTM through Mar 2026 was 47.15%, a 30269.0% increase from a year earlier, with the FY2025 full-year figure at 91.36%, up 41082.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 26.55%, down from 10.29% in the prior quarter.
- Over the last five years, EBITDA Margin for PHAT reached as high as 10.29% in Q4 2025 and fell as low as 10245.6% in Q4 2023.
- Historically, EBITDA Margin has averaged 1608.89% across 4 years, with a median of 238.41% in 2024.
- Across the five-year window, EBITDA Margin soared 1004530 bps in 2024 and surged 19001 bps in 2025, its largest moves.
- Year by year, EBITDA Margin stood at 10245.6% in 2023, then surged by 98 bps to 200.3% in 2024, then jumped by 95 bps to 10.29% in 2025, then plunged by 158 bps to 26.55% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 26.55% in Q1 2026, 10.29% in Q4 2025, and 30.85% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Phathom Pharmaceuticals | 945.22 Mn | 761.46 Mn | 46.31 Mn | -26.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.55% |
| Dec 31, 2025 | -10.29% |
| Sep 30, 2025 | -30.85% |
| Jun 30, 2025 | -151.69% |
| Mar 31, 2025 | -276.53% |
| Dec 31, 2024 | -200.30% |
| Sep 30, 2024 | -432.95% |
| Jun 30, 2024 | -1,055.43% |
| Mar 31, 2024 | -3,658.68% |
| Dec 31, 2023 | -10,245.60% |